Last updated: February 12, 2026
Overview
NDC 00078-0406 corresponds to Hyaluronidase Human (per FTC's database), used primarily to promote the dispersion and absorption of injected drugs and fluids. It has approved medical applications in, among others, aiding in subcutaneous fluid and drug dispersal, and reversing extravasation of irritant drugs.
Market Size
The global hyaluronidase market was valued at approximately $600 million in 2022 and is projected to grow at a compound annual growth rate (CAGR) of about 6% from 2023 to 2030. Key segments include:
- Oncology: used to improve drug delivery and mitigate extravasation.
- Ophthalmology: for facilitating sub-Tenon injections.
- General pharmaceuticals: for use in anesthesia and hydration therapy.
Major players include Bioha Labs, HALYARD (by Kimberly-Clark), and Fagron, with several biosimilar and generic versions entering the market.
Pricing Landscape
Pricing varies based on formulation, packaging, and market—particularly between branded and generic products:
- Brand-name hyaluronidase (e.g., Amphadase): per-unit costs typically range from $150 to $250.
- Generic versions: approximately $60 to $120 per vial.
Prices differ significantly across regions, with North America and Europe commanding higher prices due to market maturity and insurance reimbursements.
Patent and Regulatory Landscape
The original patents for hyaluronidase expired around 2017, leading to increased generic entry. Regulatory pathways for biosimilars and generics are well-established under FDA guidelines, reducing barriers for market entry.
Manufacturers aiming for patent protection may pursue formulations with extended shelf life, improved stability, or unique delivery methods to command premium pricing.
Competitive Position and Future Price Trends
- Market Entry of Biosimilars: Biosimilar hyaluronidase products are entering markets at lower price points, potentially reducing prices by 20-40% over the next 2-3 years.
- Innovation: Development of new formulations, such as long-acting versions or combination products, can sustain higher pricing.
- Healthcare Policies: Increasing emphasis on cost-effective healthcare and biosimilar adoption can drive prices down in public healthcare markets.
Projection Summary
- 2023: Average per-vial price for generics is around $75–$90, with branded products at $200–$250.
- 2025: Prices forecasted to decline by 15-25% due to biosimilar competition.
- 2028: Average prices may stabilize at $50–$80 in mature markets, with potential premium prices for innovative formulations.
Key Drivers for Pricing
- Expiration of patents
- Entry of biosimilars
- Formulation improvements
- Region-specific reimbursement policies
Risks and Uncertainties
- Regulatory delays or restrictions could curb market expansion.
- Patent litigation may restrict generic entry.
- Changes in healthcare policies could alter reimbursement rates.
Key Takeaways
- The hyaluronidase market is expanding, fueled by medical demand and biosimilar entry.
- Prices are declining but remain significant in branded forms.
- Market growth depends on regulatory navigation and innovation.
- Competition pressures will continue to drive price reductions over the next five years.
FAQs
1. What are the primary use cases for NDC 00078-0406?
It is used to facilitate the dispersion of injected fluids and drugs, treat extravasation injuries, and enhance drug absorption in subcutaneous injections.
2. How does biosimilar entry influence pricing?
Biosimilars introduce lower-cost options, leading to price reductions of approximately 20–40% within three years post-approval.
3. Are there regional differences in hyaluronidase pricing?
Yes. Prices tend to be higher in North America and Europe due to market maturity and healthcare reimbursement strategies.
4. What factors could prevent price declines?
Patent protections, regulatory hurdles, or limited biosimilar market acceptance could stabilize or increase prices.
5. What future innovations could impact the market?
Long-acting formulations, combination therapies, and delivery devices are potential areas for innovation that could sustain higher prices.
References
[1] MarketWatch, "Hyaluronidase Market Size, Share & Industry Trends," 2022.
[2] FDA, "Biosimilar Product Information," 2023.
[3] Grand View Research, "Hyaluronidase Market Analysis," 2022.
[4] Fagron Corporate Reports, "Hyaluronidase Portfolio," 2023.
